The Biologics Price Competition and Innovation (BPCIA) was passed as part of the Affordable Care Act in 2009. Now, ten years later, biosimilars have started to hit the market and it has been an interesting ride.
Panelists will discuss IP strategies going forward for both branded and biosimilar companies in light of what we know from developments in the past ten years, as well as what we can expect as we move into the next decade. Attendees will also hear whether there are other factors beyond litigation, such as complexity of the molecules and manufacturing processes, pricing, interchangeability and the breadth of approved target indications that will also contribute to the availability of biosimilars in the future.
Ability Level: All
Session ID: 504097